Nuchido

Nuchido shares the existential vulnerability of every NAD+ company — the unproven premise that raising NAD+ delivers meaningful healthspan benefit in humans — but layers on the added burden of a more complex, harder-to-explain "systems" story that is difficult to market against the simple, cheap NMN and NR products consumers already understand. Its single npj Aging study, while a credibility asset, is one small trial measuring NAD+ levels, not a demonstration of clinical outcomes like reduced disease or extended healthspan, so the peer-reviewed halo oversells what has actually been shown. Commercially, Nuchido is a small UK direct-to-consumer brand with no disclosed institutional funding, competing globally against Niagen Bioscience's public-company scale and IP, Tru Niagen's brand dominance, Jinfiniti's test-and-optimize model, and an ocean of cheaper precursor sellers — a fragmented, low-margin, high-CAC market where scientific nuance rarely wins over price and convenience. The multi-ingredient formulation is also less patent-defensible than a novel molecule; competitors can approximate the ingredient stack, and the "reactivate your own production" claim invites regulatory scrutiny over implied medical benefit under both UK and US supplement rules. Founder-scientist brands built around a single charismatic PhD are hard to scale beyond their founder's personal reach. If the NAD+ thesis deflates or a larger player replicates the systems approach at scale, Nuchido is a well-credentialed small business in a commoditizing category with no capital moat.